Dublin, June 03, 2022 (GLOBE NEWSWIRE) -- The "Global Bipolar Disorder Drugs and Treatment Market 2022-2032" report has been added to ResearchAndMarkets.com's offering.
A recent market study published on the market offers global industry analysis for 2014-2021 & opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the more important market dynamics.
After conducting thorough research on the historical and current growth parameters of the Bipolar Disorder Drugs and Treatment Market, the growth prospects of the market are obtained with maximum precision.
Market Segmentation
The Bipolar Disorder Drugs and Treatment Market is segmented in detail to cover every aspect of the market and present complete market intelligence to readers.
By Drug Class
- Mood Stabilizers
- Anticonvulsants
- Antipsychotic Drugs
- Antidepressant Drugs
- Anti-anxiety Drugs
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa (MEA)
Key Topics Covered:
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter's Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction/Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Mood Stabilizers
5.3.2. Anti-convulsants
5.3.3. Anti-psychotic Drugs
5.3.4. Anti-depressant Drugs
5.3.5. Anti-anxiety Drugs
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region
6.1. Introduction
6.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
6.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa
6.4. Market Attractiveness Analysis By Region
7. North America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8. Latin America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9. Europe Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10. Asia Pacific Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11. Middle East and Africa Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12. Key Countries Bipolar Disorder Drugs and Treatment Market Analysis
13. Market Structure Analysis
13.1. Competition Dashboard
13.2. Competition Benchmarking
13.3. Market Share Analysis of Top Players
13.3.1. By Regional
13.3.2. By Drug Class
14. Competition Analysis
14.1. Competition Deep Dive
14.1.1. AbbVie Inc.
14.1.1.1. Overview
14.1.1.2. Product Portfolio
14.1.1.3. Profitability by Market Segments
14.1.1.4. Sales Footprint
14.1.1.5. Strategy Overview
14.1.1.5.1. Marketing Strategy
14.1.2. Glaxo SmithKline (GSK)
14.1.2.1. Overview
14.1.2.2. Product Portfolio
14.1.2.3. Profitability by Market Segments
14.1.2.4. Sales Footprint
14.1.2.5. Strategy Overview
14.1.2.5.1. Marketing Strategy
14.1.3. Eli Lilly and company
14.1.3.1. Overview
14.1.3.2. Product Portfolio
14.1.3.3. Profitability by Market Segments
14.1.3.4. Sales Footprint
14.1.3.5. Strategy Overview
14.1.3.5.1. Marketing Strategy
14.1.4. Janssen Pharmaceuticals
14.1.4.1. Overview
14.1.4.2. Product Portfolio
14.1.4.3. Profitability by Market Segments
14.1.4.4. Sales Footprint
14.1.4.5. Strategy Overview
14.1.4.5.1. Marketing Strategy
14.1.5. Johnson & Johnson
14.1.5.1. Overview
14.1.5.2. Product Portfolio
14.1.5.3. Profitability by Market Segments
14.1.5.4. Sales Footprint
14.1.5.5. Strategy Overview
14.1.5.5.1. Marketing Strategy
14.1.6. Astellas Pharma Inc.
14.1.6.1. Overview
14.1.6.2. Product Portfolio
14.1.6.3. Profitability by Market Segments
14.1.6.4. Sales Footprint
14.1.6.5. Strategy Overview
14.1.6.5.1. Marketing Strategy
14.1.7. Bristol Myers Squibb
14.1.7.1. Overview
14.1.7.2. Product Portfolio
14.1.7.3. Profitability by Market Segments
14.1.7.4. Sales Footprint
14.1.7.5. Strategy Overview
14.1.7.5.1. Marketing Strategy
14.1.8. Gedeon Richter Plc.
14.1.8.1. Overview
14.1.8.2. Product Portfolio
14.1.8.3. Profitability by Market Segments
14.1.8.4. Sales Footprint
14.1.8.5. Strategy Overview
14.1.8.5.1. Marketing Strategy
14.1.9. H. Lundbeck A/S
14.1.9.1. Overview
14.1.9.2. Product Portfolio
14.1.9.3. Profitability by Market Segments
14.1.9.4. Sales Footprint
14.1.9.5. Strategy Overview
14.1.9.5.1. Marketing Strategy
14.1.10. Pfizer Inc.
14.1.10.1. Overview
14.1.10.2. Product Portfolio
14.1.10.3. Profitability by Market Segments
14.1.10.4. Sales Footprint
14.1.10.5. Strategy Overview
14.1.10.5.1. Marketing Strategy
14.1.11. Novartis AG
14.1.11.1. Overview
14.1.11.2. Product Portfolio
14.1.11.3. Profitability by Market Segments
14.1.11.4. Sales Footprint
14.1.11.5. Strategy Overview
14.1.11.5.1. Marketing Strategy
14.1.12. Otsuka Holdings Co. Ltd
14.1.12.1. Overview
14.1.12.2. Product Portfolio
14.1.12.3. Profitability by Market Segments
14.1.12.4. Sales Footprint
14.1.12.5. Strategy Overview
14.1.12.5.1. Marketing Strategy
14.1.13. Validus Pharmaceuticals LLC
14.1.13.1. Overview
14.1.13.2. Product Portfolio
14.1.13.3. Profitability by Market Segments
14.1.13.4. Sales Footprint
14.1.13.5. Strategy Overview
14.1.13.5.1. Marketing Strategy
15. Assumptions & Acronyms Used
16. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/aidrhm
